|
Post by kite on Jan 4, 2021 17:00:57 GMT -5
www.globenewswire.com/news-release/2021/01/04/2152979/0/en/MannKind-Corporation-to-Participate-in-H-C-Wainwright-Bioconnect-2021-Conference.htmlWESTLAKE VILLAGE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright Bioconnect 2021 Conference which will be available on demand starting on January 11, 2021 at 6:00 am (ET). Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company's website at www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.
|
|
|
Post by uvula on Jan 4, 2021 17:22:40 GMT -5
This was from the press release on Dec 10 when Shannon became chairman of the board: "MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide."
This is from today's press release:"MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases,...". They didn't mention Afrezza, THEIR ONLY CURRENT PRODUCT, at all.
Just seems sort of inconsistent and downright weird. Usually companies always describe themselves the same way. Is MNKD distancing itself from Afrezza?
|
|
|
Post by jlaw277 on Jan 4, 2021 17:30:35 GMT -5
Interesting both UTHR and MNKD are speaking in the AM on the same day. That seems an especially early time for MC at 6AM.
|
|
|
Post by LongMNKD on Jan 4, 2021 17:41:33 GMT -5
I agree, he's a late sleeper
|
|
|
Post by lennymnkd on Jan 4, 2021 17:56:09 GMT -5
This was from the press release on Dec 10 when Shannon became chairman of the board: "MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide." This is from today's press release:"MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases,...". They didn't mention Afrezza, THEIR ONLY CURRENT PRODUCT, at all. Just seems sort of inconsistent and downright weird. Usually companies always describe themselves the same way. Is MNKD distancing itself from Afrezza? How many times can they sell the Afrezza story to them !
|
|
|
Post by tarheelblue004 on Jan 4, 2021 18:19:20 GMT -5
This was from the press release on Dec 10 when Shannon became chairman of the board: "MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide." This is from today's press release:"MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases,...". They didn't mention Afrezza, THEIR ONLY CURRENT PRODUCT, at all. Just seems sort of inconsistent and downright weird. Usually companies always describe themselves the same way. Is MNKD distancing itself from Afrezza? Seems like they are preparing to add the partner product to their GTM message.
|
|
|
Post by letitride on Jan 4, 2021 20:00:40 GMT -5
Interesting both UTHR and MNKD are speaking in the AM on the same day. That seems an especially early time for MC at 6AM. I do believe I am going to want to hear both these presentations. And 6 AM is this a misprint? That time of the morning is reserved for Denny's after an all niter, or on my way to work not a Bio Tech presentation.
|
|
|
Post by jlaw277 on Jan 5, 2021 10:11:31 GMT -5
Interesting both UTHR and MNKD are speaking in the AM on the same day. That seems an especially early time for MC at 6AM. Follow up. They are being prerecorded from January 4-8. Not known when MC is doing his fireside chat.
|
|
|
Post by letitride on Jan 5, 2021 12:44:58 GMT -5
Interesting both UTHR and MNKD are speaking in the AM on the same day. That seems an especially early time for MC at 6AM. Follow up. They are being prerecorded from January 4-8. Not known when MC is doing his fireside chat. Where did the pre recording info come from?
|
|
|
Post by MnkdWASmyRtrmntPlan on Jan 5, 2021 12:52:32 GMT -5
Follow up. They are being prerecorded from January 4-8. Not known when MC is doing his fireside chat. Where did the pre recording info come from? It's Covid-time, so, probably from Mike's living room ... snuggling up to his electric fireplace and drinking a quarantini. Oh, I just reread your question and I realized that you said recording "info". Well, if he has enough quarantinis, maybe he will go off-script and we might get some really good info. Or, at least "entertaining" info.
|
|
|
Post by mytakeonit on Jan 5, 2021 13:12:08 GMT -5
You all do know that you have 2 weeks to do the play back? Do you really have to try to hear it live? We already know that MNKD and UTHR are partnering. And, I do have enough shares. But, that's mytakeonit BTW, I am not Jack Ma But, that's matakeonit
|
|
|
Post by jlaw277 on Jan 5, 2021 22:10:16 GMT -5
|
|
|
Post by LongMNKD on Jan 11, 2021 8:45:06 GMT -5
|
|
|
Post by Clement on Jan 11, 2021 8:59:53 GMT -5
TreT will be called "Tyvaso DPI" which makes a lot of sense for actually converting existing Tyvaso customers over to Tyvaso DPI. MC said everything (clinical trial data gathering) was completed in December and Tyvaso DPI will be "launching later this year". Part of UTHR push on timing is to get Tyvaso DPI in the upcoming trial for COPD!!
Y'all listen and check me out on that last sentence. That's what I understood.
|
|
|
Post by spikespiegel on Jan 11, 2021 9:10:05 GMT -5
and it sounds like the India Trial has startet... did i hear it right?
|
|